110 related articles for article (PubMed ID: 3523888)
1. Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor.
Foegh ML; Khirabadi BS; Rowles JR; Braquet P; Ramwell PW
Transplantation; 1986 Jul; 42(1):86-8. PubMed ID: 3523888
[No Abstract] [Full Text] [Related]
2. Prolongation of guinea pig-to-rat xenograft survival with BN 52063, a specific antagonist of platelet-activating factor.
Filipponi F; Michel A; Houssin D
Ital J Surg Sci; 1989; 19(4):325-9. PubMed ID: 2483404
[TBL] [Abstract][Full Text] [Related]
3. Platelet-activating factor and hyperacute rejection. The effect of a platelet-activating factor antagonist, SRI 63-441, on rejection of xenografts and allografts in sensitized hosts.
Makowka L; Chapman FA; Cramer DV; Qian SG; Sun H; Starzl TE
Transplantation; 1990 Sep; 50(3):359-65. PubMed ID: 2402783
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of immunosuppressive action of cyclosporine A by platelet-activating factor antagonists: an approach of the mechanism of action of these drugs in the prevention of graft rejection.
Pignol B; Henane S; Pirotzky E; Mencia-Huerta JM; Braquet P
Transplant Proc; 1988 Apr; 20(2 Suppl 2):259-65. PubMed ID: 3259039
[No Abstract] [Full Text] [Related]
5. Influence of the specific antagonist of PAF-acether, BN 52021, and of Ginkgo extract on the rejection of murine tail skin allografts and the PAF-acether mortality in mice in particular consideration of the role of TXB2.
Becker K; Braquet P; Förster W
Biomed Biochim Acta; 1988; 47(10-11):S165-8. PubMed ID: 3073760
[TBL] [Abstract][Full Text] [Related]
6. Influence of the specific antagonist of PAF-acether, BN 52021, on the rejection of murine tail skin allografts and the PAF-acether mortality in mice in particular consideration of the role of TXB2.
Becker K; Lueddeckens G; Braquet P; Förster W
Prog Clin Biol Res; 1989; 301():499-503. PubMed ID: 2798460
[No Abstract] [Full Text] [Related]
7. The effect of prednisolone, thromboxane, and platelet-activating factor receptor antagonists on lymphocyte and platelet migration in experimental cardiac transplantation.
Khirabadi BS; Foegh ML; Goldstein HA; Ramwell PW
Transplantation; 1987 May; 43(5):626-30. PubMed ID: 3033853
[TBL] [Abstract][Full Text] [Related]
8. Platelet-activating factor in organ transplant rejection.
Foegh ML; Chambers E; Khirabadi BS; Nakanishi T; Ramwell PW
Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():377-82. PubMed ID: 2526501
[No Abstract] [Full Text] [Related]
9. Proofs of involvement of PAF-acether in various immune disorders using BN 52021 (ginkgolide B): a powerful PAF-acether antagonist isolated from Ginkgo biloba L.
Braquet P
Adv Prostaglandin Thromboxane Leukot Res; 1986; 16():179-98. PubMed ID: 2949548
[No Abstract] [Full Text] [Related]
10. Anti-anaphylactic properties of BN 52021: a potent platelet activating factor antagonist.
Braquet P; Bourgain RH
Adv Exp Med Biol; 1987; 215():215-35. PubMed ID: 3314403
[No Abstract] [Full Text] [Related]
11. Prolongation of rat heart allograft survival using low-dose cyclosporine and PAF antagonist WEB 2170.
Da Costa M; Metcalfe S; Calne RY
Transplant Proc; 1990 Aug; 22(4):1945-6. PubMed ID: 2389490
[No Abstract] [Full Text] [Related]
12. Platelet-activating factor antagonist BN52021 improves survival in normothermic liver ischemia in rats.
Borobia FG; Figueras J; Escriba JM; Farran L; Rafecas A; Fabregat J; Torras J; Jaurrieta E
Transplant Proc; 1993 Aug; 25(4):2543-4. PubMed ID: 8356661
[No Abstract] [Full Text] [Related]
13. Prolongation of cardiac allograft survival by suppressor T cells (Ts) generated in vitro using cyclosporine.
Lenrow DA; Markmann JF; Shachner MS; Naji A
Transplant Proc; 1989 Feb; 21(1 Pt 1):473-4. PubMed ID: 2523144
[No Abstract] [Full Text] [Related]
14. [Renal diseases and platelet activating factor].
Pirotzky E; Colliez P; Guilmard C; Braquet P
Pediatrie; 1989; 44(3):163-7. PubMed ID: 2740184
[TBL] [Abstract][Full Text] [Related]
15. Role of platelet activating factor in kidney transplant rejection in the rat.
Butterly DW; Spurney RF; Ruiz P; Pirotzky E; Braquet P; Coffman TM
Kidney Int; 1995 Aug; 48(2):337-43. PubMed ID: 7564100
[TBL] [Abstract][Full Text] [Related]
16. Effects of the platelet-activating factor antagonist BN 52021 on the hemodynamics of rats with experimental cirrhosis of the liver.
Villamediana LM; Sanz E; Fernandez-Gallardo S; Caramelo C; Sanchez Crespo M; Braquet P; Lopez-Novoa JM
Life Sci; 1986 Jul; 39(3):201-5. PubMed ID: 3755490
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of a PAF-acether antagonist, BN 52021, in trichothecene toxicosis.
Feuerstein G; Leader P; Siren AL; Braquet P
Toxicol Lett; 1987 Oct; 38(3):271-4. PubMed ID: 3660430
[TBL] [Abstract][Full Text] [Related]
18. The role of PAF-acether in anaphylaxis demonstrated with the use of the antagonist BN 52021.
Braquet P; Guinot P; Touvay C
Agents Actions Suppl; 1987; 21():97-117. PubMed ID: 3314418
[No Abstract] [Full Text] [Related]
19. Interference of BN 52021, a PAF-acether antagonist, with endotoxin-induced hypotension in the guinea-pig.
Adnot S; Lefort J; Lagente V; Braquet P; Vargaftig BB
Pharmacol Res Commun; 1986 Aug; 18 Suppl():197-200. PubMed ID: 3774845
[No Abstract] [Full Text] [Related]
20. Prolongation of cardiac allograft survival with the PAF antagonist BN-52021 and the thromboxane receptor antagonists L640035 and L636499.
Foegh ML; Alijani MR; Helfrich GB; Khirabadi BS; Ramwell PW
Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():381-4. PubMed ID: 2936126
[No Abstract] [Full Text] [Related]
[Next] [New Search]
